← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

Aortitis

MONDO:0006656 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 45 citations openscientist · 53 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

Aortitis is not a single disease but a heterogeneous umbrella syndrome of aortic-wall inflammation spanning both infectious and noninfectious etiologies (large-vessel vasculitis, clinically isolated aortitis, IgG4-related, infectious, and drug-induced forms).

UNANIMOUS INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 95% Aortitis is an umbrella term covering multiple etiologies (infectious and noninfectious).
Falcon frames aortitis as an umbrella term / syndrome with divergent infectious and noninfectious causes and management imperatives.
openscientist CONCORDANT 95% Aortitis is a heterogeneous group of inflammatory conditions affecting the aorta, encompassing both infectious and non-infectious etiologies.
OpenScientist opens with the same heterogeneous-syndrome framing and enumerates the infectious/noninfectious subtypes.

The predominant noninfectious cause of aortitis is population-dependent: clinical case series are dominated by giant cell arteritis (~76% of cases), whereas high-sampling surgical-histology cohorts are dominated by clinically isolated aortitis (CIA, ~75% of aortitis cases; ~10.6% overall surgical prevalence).

UNANIMOUS LEAD
epidemiology
ProviderStanceScoreEvidence
falcon CONCORDANT 75% histology-sampled prevalence 10.6% with 75% CIA
Falcon's evidence base is the surgical-pathology literature, where histology-confirmed aortitis is ~10.6% and clinically isolated aortitis predominates (~75%) — a different denominator than a clinical series.
DOI:10.3390/jcdd11120405
openscientist CONCORDANT 75% are the most common causes, with GCA accounting for approximately 76% of cases in clinical series.
OpenScientist reports GCA as the most common cause at ~76% of cases in clinical series. The two figures do not conflict — they describe different sampling frames (clinical vs surgical-histology) rather than contradicting each other.

Large-vessel-vasculitis aortitis is a polygenic, multifactorial condition with strong HLA associations (HLA-DRB1*04 for GCA, HLA-B*52:01 for Takayasu arteritis) rather than a Mendelian single-gene disorder.

UNANIMOUS INTEGRATED
genetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 80% and susceptibility loci (HLA-B/MICA; HLA-DQB1/HLA-DRB1) were reported in review
Falcon reports HLA-DRB*04 for GCA and persistent genetic risk at HLA-B*52:01 plus HLA-B/MICA and HLA-DQB1/HLA-DRB1 susceptibility loci for TAK, consistent with polygenic HLA-driven susceptibility.
openscientist CONCORDANT 90% It is a complex, polygenic condition with multifactorial inheritance involving HLA and non-HLA susceptibility loci interacting with environmental triggers.
OpenScientist states the polygenic/multifactorial framing explicitly and tabulates HLA-DRB1, HLA-B (B*52:01 TAK, B*15:01 GCA) and non-HLA loci.
PMID:23843109, PMID:27815653

A Takayasu-specific mechanistic genetic axis links the MLX rs665268 (Q139R) variant to enhanced MondoA-MLX/TXNIP activity and NLRP3 inflammasome activation, driving macrophage-mediated vascular inflammation.

SINGLE LEAD
genetic_factorpathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 90% activation with increased IL-1β, oxidative stress, and impaired autophagy (mTOR axis), supporting a causal chain from genotype to macrophage-driven vascular inflammation.
Falcon develops the MLX-Q139R -> TXNIP -> NLRP3 inflammasome causal chain as a primary-research mechanistic finding specific to Takayasu arteritis.
DOI:10.1161/circgen.118.002296
openscientist SILENT —
OpenScientist's genetics section covers HLA-DRB1/HLA-B/MICA/IL12B/MFGE8/ TNF/RCAN3 but does not mention the MLX variant or the TXNIP/NLRP3 axis.

GCA/large-vessel aortitis is driven by activation of arterial-wall (adventitial) dendritic cells with Th1/Th17 CD4+ T-cell recruitment and macrophage/giant-cell activation, implicating multiple signaling cascades (NOTCH, JAK-STAT, NF-kB, TLR, VEGF).

MAJORITY INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon PARTIAL 60% initiation includes activation of arterial-wall dendritic cells, T cell invasion enabled by monocyte-derived MMP-9, NETs, macrophage polarization, and tertiary lymphoid organ signals (CXCL13/BAFF/APRIL/LT-β), implicating innate and adaptive immune circuits and stromal remodeling.
Falcon describes the same dendritic-cell -> T-cell -> macrophage immune circuit and stromal remodeling, but does not enumerate the specific named signaling pathways (NOTCH, JAK-STAT, etc.).
openscientist CONCORDANT 85% Aortitis involves at least 7 major molecular signaling pathways, with distinct signatures per subtype:
OpenScientist itemizes seven pathways (NOTCH, JAK-STAT, NF-kB, TLR, mTORC1/Notch-1, TGF-beta/fibrosis, VEGF/angiogenesis) with cited immunohistochemical and expression evidence.
PMID:21220737, PMID:29254929

Across subtypes, aortic-wall inflammation converges on structural remodeling (intimal hyperplasia, elastic-lamina/medial degradation, neovascularization, fibrosis), producing aneurysm, dissection, and stenosis/occlusion.

UNANIMOUS INTEGRATED
pathophysiologyphenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 90% arise from wall thickening, loss of elasticity, and inflammatory destruction/remodeling.
Falcon's integrated causal chain routes inflammation through structural remodeling (intimal hyperplasia, neovascularization, fibrosis, medial degradation) to aneurysm, dissection, stenosis and occlusion.
openscientist CONCORDANT 90% Aortitis carries significant morbidity through aortic aneurysm formation (up to 17-fold increased risk in GCA), dissection, and rupture
OpenScientist details vascular remodeling, MMP-2/9 elastic-lamina fragmentation and intimal hyperplasia converging on aneurysm, dissection and stenosis, with a 17-fold aneurysm risk in GCA.

First-line treatment is high-dose glucocorticoids, with the IL-6 receptor antagonist tocilizumab as an effective steroid-sparing agent in GCA (GiACTA: ~56% sustained remission vs ~14% with glucocorticoids alone).

UNANIMOUS INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 80% used for relapsing/refractory disease after failure of two conventional strategies.
Falcon anchors treatment on glucocorticoids plus methotrexate and adds tocilizumab for relapsing/refractory disease, citing the GiACTA benchmark (56%/53% vs 14%/18% sustained remission at 52 weeks).
DOI:10.1186/s13063-024-07905-4, DOI:10.3390/sci7010012
openscientist CONCORDANT 90% GiACTA: 56% sustained remission vs 14% placebo
OpenScientist reports glucocorticoids first-line with FDA-approved tocilizumab as steroid-sparing therapy, quoting the GiACTA remission figures.
PMID:41218409

The oral JAK1 inhibitor upadacitinib (15 mg) met its primary endpoint in the phase III SELECT-GCA trial (46.4% sustained remission vs 29.0% placebo), establishing JAK inhibition as an effective new therapeutic option in GCA.

SINGLE LEAD
treatment
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% upadacitinib (JAK inhibitor; phase III SELECT-GCA trial positive: 46.4% sustained remission vs 29.0% placebo, P=0.002)
OpenScientist reports the positive phase III SELECT-GCA result for upadacitinib 15 mg (46.4% vs 29.0%, P=0.002), with the 7.5 mg dose not superior to placebo.
PMID:40174237
falcon SILENT —
Falcon's treatment coverage (glucocorticoids, methotrexate, cyclophosphamide, tocilizumab, antibiotics) predates or omits the upadacitinib SELECT-GCA data and does not mention JAK inhibition.

Granulocyte-colony stimulating factor (G-CSF) is a recognized cause of drug-induced aortitis, typically presenting with fever and aortic-wall thickening days after dosing, recurring on rechallenge, and linked to the HLA-B*52 allele shared with Takayasu arteritis.

UNANIMOUS INTEGRATED
genetic_factortreatment
ProviderStanceScoreEvidence
falcon CONCORDANT 80% G-CSF exposure (notably pegfilgrastim) is associated with rare aortitis, most commonly presenting within days after dosing in the compiled case series (agent-dependent mean onset times).
Falcon characterizes G-CSF-induced aortitis from a 72-case systematic review (predominantly older women on chemotherapy, fever/pain, negative cultures, recurrence on rechallenge) but does not invoke the HLA-B*52 link.
DOI:10.3389/fphar.2024.1487501
openscientist CONCORDANT 85% G-CSF-associated aortitis linked to HLA-B52, the same allele conferring susceptibility to Takayasu arteritis, suggesting shared immunogenetic mechanisms between drug-induced and autoimmune aortitis
OpenScientist adds the HLA-B*52 immunogenetic link between G-CSF-induced and autoimmune aortitis and notes recurrence on re-exposure across G-CSF formulations.
PMID:38521841

Narrative

Overview

Both providers frame aortitis as a heterogeneous syndrome rather than a single etiology, spanning large-vessel vasculitis (GCA, Takayasu), clinically isolated surgical aortitis, infectious aortitis, IgG4-related aortitis/periaortitis, and G-CSF-associated drug-induced disease. The shared disease axis is aortic-wall inflammation driving remodeling with aneurysm, dissection, stenosis, occlusion, and the need for imaging-based surveillance.

Agreement

The reports converge on the umbrella-syndrome definition, the primacy of the large-vessel vasculitides and their HLA-driven polygenic susceptibility (HLA-DRB1*04 in GCA, HLA-B*52:01 in Takayasu), the dendritic-cell -> Th1/Th17 T-cell -> macrophage immune circuit, the convergent structural remodeling that yields aneurysm/dissection/stenosis, glucocorticoids plus steroid-sparing tocilizumab (GiACTA) as the treatment backbone, and G-CSF as a recognized drug cause with recurrence on rechallenge.

Divergence

Falcon emphasizes the surgical-pathology, imaging, and G-CSF case-review literature: it uniquely develops the Takayasu MLX-Q139R -> TXNIP -> NLRP3 inflammasome mechanistic axis and frames prevalence through a surgical-histology cohort in which clinically isolated aortitis predominates (~75%). OpenScientist is broader and more recent on treatment and genetics: it names seven signaling pathways, reports GCA as ~76% of clinical-series cases, adds the positive phase III SELECT-GCA upadacitinib result, and links G-CSF aortitis to HLA-B*52. The apparent GCA-vs-CIA predominance mismatch is a sampling-frame difference (clinical series vs surgical histology), not a true contradiction.

Integration

Integrated into kb/disorders/Aortitis.yaml: the umbrella-syndrome framing and multi-etiology scope; HLA polygenic susceptibility; the GCA immunopathology and convergent structural-remodeling causal chain; glucocorticoid + tocilizumab treatment with GiACTA support; clinically isolated aortitis and its surveillance recommendations; and G-CSF drug-induced aortitis with the HLA-B*52 recurrence signal.

Not integrated (leads)

Retained as leads rather than promoted: the Takayasu-specific MLX-Q139R/ NLRP3 mechanistic axis, the upadacitinib/SELECT-GCA JAK-inhibitor evidence (a GCA-context therapy whose aortitis-specific remodeling endpoints remain uncertain), and the finer-grained biomarker and imaging-prognosis details.

Cross-provider synthesis comparing two independent Aortitis deep-research reports: falcon (surgical-pathology/imaging/case-review focused) and openscientist (comprehensive 15-domain). No direct contradictions were found; divergence is coverage/recency plus a sampling-frame difference on the predominant noninfectious cause (clinical-series GCA vs surgical-cohort CIA). All best_matching_text values are verbatim excerpts from the cited report files; provider citations are recorded as leads pending fetch-reference verification of the underlying PMIDs/DOIs.